



# Advancing research in oncology

## Unlock the potential of genomic data

The information within the human genome can help us diagnose rare diseases, identify individuals at risk for developing certain conditions and create effective treatment regimens. But today's genomic data sets come with limitations for researchers. They're noisy, not representative and, if not linked to the longitudinal clinical data that detail patients' journeys, their value is limited.

## Clinicogenomic data as a catalyst for research

Research-ready, de-identified clinicogenomics data sets link genomic data with the longitudinal health record. This allows for:

- Genotypic and phenotypic research across all stages of a therapy's development and use in the real world
- Improved understanding of medical conditions and the criteria used to diagnose them
- The creation of cohorts that reflect the real-world populations a researcher wants to study

## Biomarker-driven cancer care is on the rise

Precision medicine and targeted treatments are on the rise. Research shows that two-thirds of the 2021 FDA-approved drugs were supported by human genetics evidence.\* However, because a cancer patient's journey often begins prior to oncology care, data that reveal what steps led to a cancer diagnosis are often siloed and disconnected. Now with clinicogenomics data from Optum, researchers can explore the clinical and genomic pillars that enable precision medicine, reveal the entire patient journey both before and after diagnosis, and help uncover new information about specific cancer types.

### Clinicogenomic data sets for oncology

<b>Tumor types</b>	Pan-tumor
<b>Gene counts</b>	Hundreds
<b>Biomarker counts</b>	Hundreds of thousands
<b>Build cohorts by</b>	Tumor type, biomarker or pathway

### Sequential sequencing for over 10% of individuals

This is important because tumor biology changes over time and in reaction to different treatments.

\* Source: <https://www.nature.com/articles/d41573-022-00120-3>.

## Research-ready, on-demand data sets

- Ignite discovery using consistently high-quality broad panel, next-generation sequencing (NGS) data
- Access a highly characterized, relevant cohort without time and cost of recruitment. Data sets are often ready for timely delivery.
- Explore robust, longitudinal phenotypic data that's linked to genomic data and designed to help you answer specific research questions about populations that matter


## Two solutions to help you find the answers you need

Life sciences leaders trust our robust real-world data and experienced consultants to connect the dots in ways that answer tough questions, illuminate new possibilities and improve patients' lives.

The Optum clinicogenomics portfolio offers solutions that scale to help you find answers to the questions you have today – and the questions you didn't even know you could ask.

**Custom research projects** give you the flexibility to work with us on more complex initiatives that help answer unique questions. These projects can range from light-touch analytics on demand to end-to-end research work or a deep dive into a specific area.

**On-demand data sets** are easy to access, research-ready and syndicated for large market opportunities.



Screenshot of user view, data license delivered in genomics platform

## Fuel your next discovery

Optum clinicogenomics expands our capacity to deliver data-driven insights in ways that streamline the process of drug research and development. Partner with Optum clinicogenomics to:

- Discover high-value biomarkers for drug development
- Require fewer internal resources for data storage
- Waste less time on unproductive research and development
- Understand the genetic testing landscape and barriers to access
- Accelerate speed to market for innovative, targeted therapies
- Serve as more cost-effective, time-efficient digital control arm for clinical trials

[optum.com/clinicogenomics](https://optum.com/clinicogenomics)



optum.com

Optum is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

©2022 Optum, Inc. All rights reserved. WF8439568 10/22